The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | FFCD 1709-SIRTCI: selective internal radiation therapy + xelox, bevacizumab and atezolizumab in mCRC
David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, provides an overview of the ongoing Phase II FFCD 1709-SIRTCI (NCT04659382) trial evaluating the safety and efficacy of selective internal radiation therapy plus xelox, bevacizumab and atezolizumab in liver-dominant metastatic colorectal cancer (mCRC). The primary outcome is progression-free survival (PFS). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
